Cargando…
Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples
INTRODUCTION: Subjective cognitive decline (SCD) in cognitively unimpaired older individuals has been recognized as an early clinical at-risk state for Alzheimer’s disease (AD) dementia and as a target population for future dementia prevention trials. Currently, however, SCD is heterogeneously defin...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337830/ https://www.ncbi.nlm.nih.gov/pubmed/30654834 http://dx.doi.org/10.1186/s13195-018-0463-y |
_version_ | 1783388341338636288 |
---|---|
author | Wolfsgruber, Steffen Molinuevo, José Luis Wagner, Michael Teunissen, Charlotte E. Rami, Lorena Coll-Padrós, Nina Bouwman, Femke H. Slot, Rosalinde E. R. Wesselman, Linda M. P. Peters, Oliver Luther, Katja Buerger, Katharina Priller, Josef Laske, Christoph Teipel, Stefan Spottke, Annika Heneka, Michael T. Düzel, Emrah Drzezga, Alexander Wiltfang, Jens Sikkes, Sietske A. M. van der Flier, Wiesje M. Jessen, Frank |
author_facet | Wolfsgruber, Steffen Molinuevo, José Luis Wagner, Michael Teunissen, Charlotte E. Rami, Lorena Coll-Padrós, Nina Bouwman, Femke H. Slot, Rosalinde E. R. Wesselman, Linda M. P. Peters, Oliver Luther, Katja Buerger, Katharina Priller, Josef Laske, Christoph Teipel, Stefan Spottke, Annika Heneka, Michael T. Düzel, Emrah Drzezga, Alexander Wiltfang, Jens Sikkes, Sietske A. M. van der Flier, Wiesje M. Jessen, Frank |
author_sort | Wolfsgruber, Steffen |
collection | PubMed |
description | INTRODUCTION: Subjective cognitive decline (SCD) in cognitively unimpaired older individuals has been recognized as an early clinical at-risk state for Alzheimer’s disease (AD) dementia and as a target population for future dementia prevention trials. Currently, however, SCD is heterogeneously defined across studies, potentially leading to variations in the prevalence of AD pathology. Here, we compared the prevalence and identified common determinants of abnormal AD biomarkers in SCD across three European memory clinics participating in the European initiative on harmonization of SCD in preclinical AD (Euro-SCD). METHODS: We included three memory clinic SCD samples with available cerebrospinal fluid (CSF) biomaterial (IDIBAPS, Barcelona, Spain, n = 44; Amsterdam Dementia Cohort (ADC), The Netherlands, n = 50; DELCODE multicenter study, Germany, n = 42). CSF biomarkers (amyloid beta (Aβ)42, tau, and phosphorylated tau (ptau181)) were centrally analyzed in Amsterdam using prespecified cutoffs to define prevalence of pathological biomarker concentrations. We used logistic regression analysis in the combined sample across the three centers to investigate center effects with regard to likelihood of biomarker abnormality while taking potential common predictors (e.g., age, sex, apolipoprotein E (APOE) status, subtle cognitive deficits, depressive symptoms) into account. RESULTS: The prevalence of abnormal Aβ42, but not tau or ptau181, levels was different across centers (64% DELCODE, 57% IDIBAPS, 22% ADC; p < 0.001). Logistic regression analysis revealed that the likelihood of abnormal Aβ42 (and also abnormal tau or ptau181) levels was predicted by age and APOE status. For Aβ42 abnormality, we additionally observed a center effect, indicating between-center heterogeneity not explained by age, APOE, or the other included covariates. CONCLUSIONS: While heterogeneous frequency of abnormal Aβ42 was partly explained by between-sample differences in age range and APOE status, the additional observation of center effects indicates between-center heterogeneity that may be attributed to different recruitment procedures. These findings highlight the need for the development of harmonized recruitment protocols for SCD case definition in multinational studies to achieve similar enrichment rates of preclinical AD. |
format | Online Article Text |
id | pubmed-6337830 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63378302019-01-23 Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples Wolfsgruber, Steffen Molinuevo, José Luis Wagner, Michael Teunissen, Charlotte E. Rami, Lorena Coll-Padrós, Nina Bouwman, Femke H. Slot, Rosalinde E. R. Wesselman, Linda M. P. Peters, Oliver Luther, Katja Buerger, Katharina Priller, Josef Laske, Christoph Teipel, Stefan Spottke, Annika Heneka, Michael T. Düzel, Emrah Drzezga, Alexander Wiltfang, Jens Sikkes, Sietske A. M. van der Flier, Wiesje M. Jessen, Frank Alzheimers Res Ther Research INTRODUCTION: Subjective cognitive decline (SCD) in cognitively unimpaired older individuals has been recognized as an early clinical at-risk state for Alzheimer’s disease (AD) dementia and as a target population for future dementia prevention trials. Currently, however, SCD is heterogeneously defined across studies, potentially leading to variations in the prevalence of AD pathology. Here, we compared the prevalence and identified common determinants of abnormal AD biomarkers in SCD across three European memory clinics participating in the European initiative on harmonization of SCD in preclinical AD (Euro-SCD). METHODS: We included three memory clinic SCD samples with available cerebrospinal fluid (CSF) biomaterial (IDIBAPS, Barcelona, Spain, n = 44; Amsterdam Dementia Cohort (ADC), The Netherlands, n = 50; DELCODE multicenter study, Germany, n = 42). CSF biomarkers (amyloid beta (Aβ)42, tau, and phosphorylated tau (ptau181)) were centrally analyzed in Amsterdam using prespecified cutoffs to define prevalence of pathological biomarker concentrations. We used logistic regression analysis in the combined sample across the three centers to investigate center effects with regard to likelihood of biomarker abnormality while taking potential common predictors (e.g., age, sex, apolipoprotein E (APOE) status, subtle cognitive deficits, depressive symptoms) into account. RESULTS: The prevalence of abnormal Aβ42, but not tau or ptau181, levels was different across centers (64% DELCODE, 57% IDIBAPS, 22% ADC; p < 0.001). Logistic regression analysis revealed that the likelihood of abnormal Aβ42 (and also abnormal tau or ptau181) levels was predicted by age and APOE status. For Aβ42 abnormality, we additionally observed a center effect, indicating between-center heterogeneity not explained by age, APOE, or the other included covariates. CONCLUSIONS: While heterogeneous frequency of abnormal Aβ42 was partly explained by between-sample differences in age range and APOE status, the additional observation of center effects indicates between-center heterogeneity that may be attributed to different recruitment procedures. These findings highlight the need for the development of harmonized recruitment protocols for SCD case definition in multinational studies to achieve similar enrichment rates of preclinical AD. BioMed Central 2019-01-17 /pmc/articles/PMC6337830/ /pubmed/30654834 http://dx.doi.org/10.1186/s13195-018-0463-y Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Wolfsgruber, Steffen Molinuevo, José Luis Wagner, Michael Teunissen, Charlotte E. Rami, Lorena Coll-Padrós, Nina Bouwman, Femke H. Slot, Rosalinde E. R. Wesselman, Linda M. P. Peters, Oliver Luther, Katja Buerger, Katharina Priller, Josef Laske, Christoph Teipel, Stefan Spottke, Annika Heneka, Michael T. Düzel, Emrah Drzezga, Alexander Wiltfang, Jens Sikkes, Sietske A. M. van der Flier, Wiesje M. Jessen, Frank Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples |
title | Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples |
title_full | Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples |
title_fullStr | Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples |
title_full_unstemmed | Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples |
title_short | Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples |
title_sort | prevalence of abnormal alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three european memory clinic samples |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337830/ https://www.ncbi.nlm.nih.gov/pubmed/30654834 http://dx.doi.org/10.1186/s13195-018-0463-y |
work_keys_str_mv | AT wolfsgrubersteffen prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT molinuevojoseluis prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT wagnermichael prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT teunissencharlottee prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT ramilorena prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT collpadrosnina prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT bouwmanfemkeh prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT slotrosalindeer prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT wesselmanlindamp prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT petersoliver prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT lutherkatja prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT buergerkatharina prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT prillerjosef prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT laskechristoph prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT teipelstefan prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT spottkeannika prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT henekamichaelt prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT duzelemrah prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT drzezgaalexander prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT wiltfangjens prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT sikkessietskeam prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT vanderflierwiesjem prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT jessenfrank prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples AT prevalenceofabnormalalzheimersdiseasebiomarkersinpatientswithsubjectivecognitivedeclinecrosssectionalcomparisonofthreeeuropeanmemoryclinicsamples |